The Food and Drug Administration on Friday approved the first drug that benefits patients with lung cancer caused by a specific genetic mutation to a protein called KRAS, a target that for decades was considered to be “undruggable.”
The new medicine, a pill called Lumakras, was developed by Amgen.
Lumakras was cleared to treat patients with advanced non-small cell lung cancer containing a specific type of KRAS alteration called G12C. The mutation, previously untreatable, is found in approximately 13% of lung tumors.
About the Author Reprints
